Xenon Pharmaceuticals Inc. — Q3 2021 Form 10-Q
Reporting period: Three and nine months ended September 30, 2021. Unless otherwise stated, amounts are U.S. dollars in millions. Xenon is a clinical-stage biopharmaceutical company focused on neurological disorders, particularly epilepsy; it had no product sales.
Financial performance and liquidity
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | $8.1 | $6.6 | $14.7 | $27.0 |
| Research and development | $18.9 | $13.0 | $53.6 | $35.6 |
| General and administrative | $4.8 | $3.2 | $15.3 | $9.8 |
| Operating loss | $(15.6) | $(9.7) | $(54.2) | $(18.4) |
| Net loss | $(15.4) | $(8.9) | $(53.3) | $(16.5) |
| Basic and diluted loss per common share | $(0.36) | $(0.25) | $(1.29) | $(0.47) |
Gross margin is not separately reported; revenue came from collaboration and licensing arrangements rather than product sales. At September 30, cash and cash equivalents were $87.8 million and marketable securities were $161.8 million, totaling $249.6 million. Current assets were $256.3 million and current liabilities were $12.9 million. The company reported no outstanding term loan; operating lease liabilities totaled $3.2 million, including $0.7 million current.
For the first nine months, operating cash use was $48.8 million, investing cash use was $31.3 million, and financing provided $123.6 million. Cash and cash equivalents increased $42.8 million to $87.8 million. The accumulated deficit was $331.8 million.
Material changes versus comparable periods
- Nine-month revenue declined $12.3 million year over year, principally because the 2020 period included substantial recognition of deferred Neurocrine collaboration revenue as license obligations were completed. In 2021, revenue included a $5.3 million Neurocrine milestone and $3.0 million of Flexion milestones.
- Q3 revenue increased $1.6 million year over year, including the $5.3 million Neurocrine milestone, partly offset by lower recognition of deferred revenue.
- Nine-month R&D expense rose $18.0 million, driven mainly by XEN1101, XEN496, and preclinical and discovery programs. G&A increased $5.4 million, including higher stock-based compensation, personnel, intellectual-property legal fees, and market research.
- Operating cash use increased $13.8 million year over year, reflecting higher development and administrative spending and lower interest income.
Outlook, programs, risks, and unusual items
- XEN1101: On October 4, 2021, after quarter-end, Xenon announced positive topline Phase 2b X-TOLE results in focal epilepsy. The trial met its primary endpoint; median monthly seizure-frequency reductions were 52.8%, 46.4%, and 33.2% at the 25 mg, 20 mg, and 10 mg doses, versus 18.2% for placebo. Management anticipated an FDA end-of-Phase 2 meeting in Q2 2022 and estimated initiating Phase 3 in the second half of 2022. A company-sponsored MDD study was expected to begin in H1 2022.
- XEN496: The EPIK Phase 3 study in pediatric KCNQ2-DEE was underway; completion was anticipated in H1 2023. COVID-19-related site initiation and enrollment remained risks.
- Partnered programs: Neurocrine was advancing NBI-921352 in Phase 2 studies. Flexion’s FX301 Phase 1b study was expanded, with data anticipated in Q1 2022. Xenon remains dependent on collaborators’ development and commercialization decisions.
- Management expected significant expenses and operating losses for the foreseeable future, with R&D remaining the largest expense category. Before the subsequent offering, management expected September 30 cash, equivalents, and marketable securities to fund operations for at least 12 months, subject to assumptions and development spending.
- Subsequent financing: An October 2021 public offering was completed October 8, raising $324.3 million net of underwriting discounts and commissions, before offering expenses. This materially strengthened liquidity but involved substantial share issuance and dilution.
- Key risks include clinical-trial failure or delay, patient recruitment, regulatory uncertainty, reliance on third-party manufacturers and collaborators, intellectual-property protection, COVID-19 impacts, foreign-exchange exposure, and the need for future financing. No material legal proceedings were reported. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Review the complete X-TOLE data and forthcoming FDA feedback; the reported results were topline and released after quarter-end.
- Track XEN496 enrollment, site activation, and the expected H1 2023 study completion, including any continuing pandemic effects.
- Confirm the October offering’s final net proceeds after offering expenses and assess dilution, including pre-funded warrants and equity awards.
- Monitor collaboration milestones, Neurocrine’s NBI-921352 progress, and Flexion’s FX301 trial and data timing.
- Assess cash burn against development plans and runway; Xenon reported continuing losses and no product revenue, and its runway estimate depends on assumptions.